MIRAMAR, Fla., Feb. 12, 2020 (GLOBE NEWSWIRE) -- G
Post# of 36568
(Total Views: 341)
Posted On: 02/12/2020 9:03:53 AM
MIRAMAR, Fla., Feb. 12, 2020 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) today announced call-in details for the upcoming investor conference call on Thursday February 13th 2020 at 11:00am AM Eastern time.
The access information for the investor conference call is as follows:
Domestic US/Canada – 1-877-830-2591
Direct Toll / International – 1-785-424-1738
Program Title: Generex Biotechnology Conference Call
Conference ID – 9468
Agenda
− 2019-nCOV Coronavirus Initiatives
− 5/2 dividend, for every 5 shares of Generex you own you receive 2 new shares and 5/2
Dividend, for every 5 shares of Generex you own you receive 2 new shares of NuGenerex
Immuno-Oncology
− ALTuCELL Closing
− S1 funding update
− Nasdaq listing update
− NGIO spinout directly to Nasdaq
− Arizona operations Update
On the call, Mr. Moscato and his team will provide an overview of how NuGenerex Immuno-Oncology’s Ii-key technology is clinically proven to activate the immune system against numerous viruses including H5N1 avian influenza virus and a review of work with development partners & government agencies to implement Ii-Key peptide vaccines to implement a rapid response vaccination strategy that can provide immunity to the 2019-nCOV and Avian influenza (Bird Flu). Additionally, management will discuss the opportunity for NuGenerex Diagnostics to develop a rapid test for 2019-nCOV in respiratory and blood samples using its proprietary NGDx Express 2 rapid diagnostic technology.
The access information for the investor conference call is as follows:
Domestic US/Canada – 1-877-830-2591
Direct Toll / International – 1-785-424-1738
Program Title: Generex Biotechnology Conference Call
Conference ID – 9468
Agenda
− 2019-nCOV Coronavirus Initiatives
− 5/2 dividend, for every 5 shares of Generex you own you receive 2 new shares and 5/2
Dividend, for every 5 shares of Generex you own you receive 2 new shares of NuGenerex
Immuno-Oncology
− ALTuCELL Closing
− S1 funding update
− Nasdaq listing update
− NGIO spinout directly to Nasdaq
− Arizona operations Update
On the call, Mr. Moscato and his team will provide an overview of how NuGenerex Immuno-Oncology’s Ii-key technology is clinically proven to activate the immune system against numerous viruses including H5N1 avian influenza virus and a review of work with development partners & government agencies to implement Ii-Key peptide vaccines to implement a rapid response vaccination strategy that can provide immunity to the 2019-nCOV and Avian influenza (Bird Flu). Additionally, management will discuss the opportunity for NuGenerex Diagnostics to develop a rapid test for 2019-nCOV in respiratory and blood samples using its proprietary NGDx Express 2 rapid diagnostic technology.
(0)
(0)